Equities researchers at TD Cowen assumed coverage on shares of Sionna Therapeutics (NASDAQ:SION – Get Free Report) in a note issued to investors on Tuesday,Briefing.com Automated Import reports. The firm set a “buy” rating on the stock.
Several other equities analysts also recently weighed in on SION. Guggenheim initiated coverage on Sionna Therapeutics in a research report on Tuesday. They set a “buy” rating and a $45.00 target price on the stock. Stifel Nicolaus initiated coverage on shares of Sionna Therapeutics in a research note on Tuesday. They set a “buy” rating and a $32.00 price objective for the company.
Check Out Our Latest Stock Analysis on Sionna Therapeutics
Sionna Therapeutics Trading Up 4.6 %
Sionna Therapeutics Company Profile
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
See Also
- Five stocks we like better than Sionna Therapeutics
- High Flyers: 3 Natural Gas Stocks for March 2022
- Mediterranean Growth Monster: CAVA Keeps Surging—Buy the Dip?
- Insider Trades May Not Tell You What You Think
- Is the S&P 500 Ready to Rally? A $1.8M Bet on SPY Says Yes
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Consumer Spending Is Slowing—But These Stocks Will Still Thrive
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
